Paraoxonase 1 activity in subchronic low-level inorganic arsenic exposure through drinking water

Environmental Toxicology

Volumn 31, Issue 2, 2016, Pages 154-162

  Afolabi, Olusegun K ^a,b   Wusu, Adedoja D ^a,c   Ogunrinola, Olufunmilayo O ^a,c   Abam, Esther O ^a   Babayemi, David O ^a   Dosumu, Oluwatosin A ^a   Onunkwor, Okechukwu B ^a   Balogun, Elizabeth A ^a,d   Odukoya, Olusegun O ^a   Ademuyiwa, Oladipo ^a  

^a FEDERAL UNIVERSITY OF AGRICULTURE   (Nigeria)

^b LADOKE AKINTOLA UNIVERSITY OF TECHNOLOGY   (Nigeria)

^c LAGOS STATE UNIVERSITY   (Nigeria)

^d UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Arsenic exposure; Drinking water; Paraoxonase

Indexed keywords

ARSENIC; BRAIN; CARDIOLOGY; CHOLESTEROL; DISEASES; ENZYMES; SODIUM;

ARSENIC EXPOSURE; CARDIO-VASCULAR DISEASE; CARDIO-VASCULAR RISK FACTORS; EPIDEMIOLOGICAL STUDIES; INORGANIC ARSENIC; MEMBRANE FLUIDITY; PARAOXONASE; SODIUM ARSENITE;

POTABLE WATER;

ARSENATE SODIUM; ARSENITE SODIUM; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; DRINKING WATER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARAOXON; PHENYLACETIC ACID; PHOSPHOLIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSECTICIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANOARSENIC DERIVATIVE; PHENYLACETIC ACID DERIVATIVE; PON 1 PROTEIN, RAT; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WATER POLLUTANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARSENIC POISONING; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER MICROSOME; MALE; MEMBRANE FLUIDITY; MICROSOME; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; TOXICITY; WATER POLLUTANT; WISTAR RAT;

RATTUS;

ANIMALS; ARSENICALS; ARYLDIALKYLPHOSPHATASE; BRAIN CHEMISTRY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING WATER; INSECTICIDES; MALE; MICROSOMES; MICROSOMES, LIVER; PARAOXON; PHENYLACETATES; RATS; RATS, WISTAR; WATER POLLUTANTS, CHEMICAL;

EID: 84953838627     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.22030     Document Type: Article

References (48)

1. Allain CC, Poon LS, Clau CSG, Richmond WY, Fu PD. 1974. Enzymatic determination of total serum cholesterol. Clin Chem 20:470-478.
2. Andrew AS, Bernado V, Warnke LA, Davey JC, Hampton T, Mason RA, Thorpe JE, Ihnat MA, Hamilton JW. 2007. Exposure to arsenic at levels found in U.S. drinking water modifies expression in the mouse lung. Toxicol Sci 100:75-87.
3. Bryk B, BenMoyal-Segal L, Podoly E, Livnah O, Eisenkraft A, Luria S, Cohen A, Yeyezkelli Y, Hourvitz A, Soreq H. 2005. Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J Neurochem 92:1216-1227.
4. Chen Y, Graziano JH, Parvez F, Liu M, Slavkovich V, Kalra T. 2011. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: Prospective cohort study. BMJ 342:d2431.
5. Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD. 2006. Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol 36:99-133.
6. Costa LG, Cole TB, Furlong CE. 2005a. Paraoxonase (PON 1): From toxicology to cardiovascular medicine. Acta Biomed Suppl 2:50-57.
7. Costa LG, Vitalone A, Cole TB, Furlong CE. 2005b. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550.
8. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301-4308.
9. Deakin S, Moren X, James RW. 2005. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 179:17-25.
10. Deakin SP, Bioletto S, Bochaton-Piallat M-L, James RW. 2011. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Rad Biol Med 50:102-109.
11. Debord J, Bollinger JC, Merle L, Dantoine T. 2003. Inhibition of human serum arylesterase by metal chlorides. J Inorg Biochem 94:1-4.
12. Elsenhans B, Ademuyiwa O, Schmolke G, Scharper J, Hunder G. 1993. Arsenic-copper interactions in the kidneys of laboratory animals. In: Elsenhans B, Forth W, Schümann K, editors. Metal-Metal Interactions. Gütersloh, Germany: Bertelsmann Foundation Publishers. p 110-128.
13. Ferré N, Camps J, Cabré M, Paul A, Joven J. 2001. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50:997-1000.
14. Folch J, Lees M, Sloane SGH. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509.
15. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. 1988. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 43:230-238.
16. Gidez LT, Miller GH, Burnstein M, Slagle S, Eder HA. 1982. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23:1206-1223.
17. Gil F, Gonzalvo MC, Hernandez AF, Villanueva E, Pla A. 1994. Differences in the kinetic properties, effect of calcium and sensitivity to inhibitors of paraoxon hydrolase activity in rat plasma and microsomal fraction from rat liver. Biochem Pharmacol 48:1559-1568.
18. Gonzalvo MC, Gil F, Hernández AF, Villanueva E, Pla A. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem-Biol Interact 105:169-179.
19. Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. 1998. Human liver paraoxonase (PON1): Subcellular distribution and characterization. J Biochem Mol Toxicol 12:61-69.
20. Harrison R, Lunt GG. 1975. Biologica Membranes. Their Structure and Function; Glasgow, Scotland: Blackie and Son Limited.
21. Huen K, Harley K, Bradman A, Eskenazi B, Holland N. 2010. Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol 244:181-189.
22. Hughes MF, Beck BD, Chen Y, Lewis AS, Thomas DJ. 2011. Arsenic exposure and toxicology: A historical perspective. Toxicol Sci 123:305-332.
23. Hunder G, Scharper J, Ademuyiwa O, Elsenhans B. 1999. Species differences in arsenic-mediated renal copper accumulation: Acomparison between rats, mice and guinea-pigs. Hum Exp Toxicol 18:699-705.
24. James RW, Deakin SP. 2004. The importance of high density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 37:1986-1994.
25. Junge W, Klees H. 1984. Arylesterase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis, 3rd Ed. Weinheim, Germany: Verlag Chemie. p 8-14.
26. Keizer HG. 2012. The "Mevalonate-hypothesis": A cholesterol-independent alternative for the etiology of atherosclerosis. Lipids Health Dis 11:149.
27. Kosaka T, Yamaguchi M, Motomura T, Mizuno K. 2005. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta 359:156-162.
28. Kriketos AD, Furler SM, Gan SK, Poynten AM, Chisholm DJ, Campbell LV. 2003. Multiple indexes of lipid availability are independently related to whole body insulin action in healthy humans. J Clin Endocr Met 88:793-798.
29. Li WF, Sun C-W, Cheng T-J, Chang K-H, Chen C-J, Wang S-L. 2009. Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) among arsenic exposed residents in Southwestern Taiwan. Toxicol Appl Pharmacol 236:246-253.
30. Li YR, Zhu H, Kauffman M, Danelisen I, Misra HP, Ke Y, Jia Z. Paraoxonases function as unique protectors against cardiovascular diseases and diabetes: Updated experimental and clinical data. Exp Biol Med (Maywood) (in press). DOI: 10.1177/1535370214535897.
31. Liu T, Zhang X, Zhang J, Liang Z, Cai W, Huang M, Yan C, Zhu Z, Han Y. Association between PON1 rs662 polymorphism and coronary artery disease. Eur J Clin Nutr (in Press). DOI:10:1038/ejcn.2014.105.
32. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107:2775-2779.
33. Marsillach J, Aragonès G, Mackness B, Mackness M, Rull A, Beltrán-Debón R, Pedro-Botet J, Allonso-Villaverde C, Joven J, Camps J. 2010. Decreased paraoxonase-1 activity is associated with alterations of high density lipoprotein particles in chronic liver impairment. Lipids Health Dis 9:46.
34. Mazumder DG, Dasgupta UB. 2011. Chronic arsenic toxicity: Studies in West Bengal, India. Kaohsiung J Med Sci 27:360-370.
35. Nguyen SD, Kim JR, Kim MR, Jung TS, Soka DE. 2004. Copper ions and hypochlorite are mainly responsible for oxidative inactivation of paraoxon-hydrolyzing activity in human high density lipoprotein. Toxicol Lett 147:201-208.
36. Rodrigo L, Hernández AF, López-Caballero J, Gil F, Pla A. 2001. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue: Implications for its physiological role. Chem Biol Interact 137:123-137.
37. Román DA, Pizarro I, Rivera L, Cámara C, Palacios MA, Gómez MM, Solar C. 2011. An approach to the arsenic status in cardiovascular tissues in patients with coronary heart disease. Hum Exp Toxicol 30:1150-1164.
38. Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, Gortner DA, Boyko E, Schellenberg GD, Furlong CE, Jarvik GP. 2005. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 46:1888-1895.
39. Rueckschloss U. 2004. NADPH oxidase in endothelial cells: Impact on atherosclerosis. Antioxid Redox Signal 5:171-180.
40. Smeester L, Rager JE, Bailey KA, Guan X, Smith N, Garcia-Vargas G, Del Razo L-M, Drobná Z, Kelkar H, Stýblo M, Fry RC. 2011. Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol 24:165-167.
41. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. 1999. Human serum paraoxonase/arylesterase retained hydrophobic N-terminal sequence associates with HDLs by binding phospholipids: Apoprotein A-1 stabilises activity. Arterioscler Thromb Vasc Biol 19:2214-2225.
42. States JC, Srivastava S, Chen Y, Barchowsky A. 2009. Arsenic and cardiovascular disease. Toxicol Sci 107:312-323.
43. Stewart JCM. 1980. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104:10-14.
44. Styblo M, Del Razo LM, LeClusyse EL, Hamilton GA, Wang C, Cullen WR, Thomas DJ. 1999. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol 12:560-565.
45. Suwalsky M, Rivera C, Sotomayor CP, Jemiola-Rzeminsky M, Strzalka K. 2008. Monomethylarsonate (MMA v) exerts stronger effects than arsenate on the structure and thermotropic properties of phospholipids bilayers. Biophys Chem 132:1-8.
46. Vahter M. 1981. Biotransformation of trivalent and pentavalent inorganic arsenic in mice and rats. Environ Res 25:286-293.
47. Xie Y, Trouba KJ, Liu J, Waalkes MP, Germolec DR. 2004. Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.Ac) mice. Environ Health Perspect 112:1255-1263.
48. Yamamoto S, Konishi Y, Matsuda T, Murai T, Shibata M-A, Matsui-Yuasa I, Otani S, Kuroda K, Endo G, Fukushima S. 1995. Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res 55:1271-1276.